The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

GLP-1 agonists for weight loss are now commonly used for adults, but might they also be an effective treatment for younger ...

GLP-1s currently used for weight loss—although not all are expressly approved for this purpose—include Ozempic and Wegovy (semaglutide), Victoza and Saxenda (liraglutide), and Mounjaro and ...

The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the conventional injected liraglutide (Saxenda®).

Apart from Victoza, which was approved for Type 2 diabetes in 2010, liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy ...